Appco Pharma LLC has recalled 2,256 bottles of Ranitidine capsules, a prescription medication used to treat stomach acid conditions. The recall affects both 150 mg and 300 mg strengths packaged in 30, 60, and 500-count bottles. This action was taken because testing detected N-nitrosodimethylamine (NDMA), a substance classified as a probable human carcinogen, at levels that deviate from manufacturing standards. Consumers should contact their healthcare provider or pharmacist to discuss alternative treatments and instructions for returning the product.
The drug contains NDMA, an impurity that is classified as a probable human carcinogen based on laboratory testing. While low levels of NDMA are common in some foods and water, high exposure over time may increase the risk of cancer.
Healthcare consultation and pharmaceutical refund
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.